Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)

Ertugliflozin, 5 mg or 15 mg, administered orally, once daily for 26 weeks.

Sitagliptin, 100 mg, administered orally, once daily for 26 weeks.

Matching placebo to ertugliflozin administered orally, once daily for 26 weeks.

Matching placebo to sitagliptin administered orally, once daily for 26 weeks.

Open-label glimepiride rescue therapy will be initiated at 1 or 2 mg/day and may be titrated to the maximum labeled dose or maximum tolerated dose (if lower than labeled dose), as considered appropriate by the investigator, based on blood glucose measurements and in accordance with the local, approved label.